Use of favipiravir to treat lassa virus infection in Macaques

Emerging Infectious Diseases

Volumn 24, Issue 9, 2018, Pages 1696-1699

  Rosenke, Kyle ^a   Feldmann, Heinz ^a,b   Westover, Jonna B ^c   Hanley, Patrick William ^a   Martellaro, Cynthia ^a   Feldmann, Friederike ^a   Saturday, Greg ^a   Lovaglio, Jamie ^a   Scott, Dana P ^a   Furuta, Yousuke ^d   Komeno, Takashi ^d   Gowen, Brian B ^c   Safronetz, David ^b,e  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UTAH STATE UNIVERSITY   (United States)

^d TOYAMA CHEMICAL CO LTD   (Japan)

^e PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; FAVIPIRAVIR; PLACEBO; PROTEIN; VIRUS RNA; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FATTY LIVER; FEMALE; HEPATITIS; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; IN SITU HYBRIDIZATION; LASSA VIRUS; LOADING DRUG DOSE; MACACA FASCICULARIS; NEUTROPHIL; NONHUMAN; PLATELET COUNT; REAL TIME POLYMERASE CHAIN REACTION; VIRUS INFECTION; VIRUS STRAIN; ANIMAL; ISOLATION AND PURIFICATION; LASSA FEVER; MACACA; MONKEY DISEASE; RANDOMIZATION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VETERINARY MEDICINE;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; FEMALE; INJECTIONS, SUBCUTANEOUS; LASSA FEVER; LASSA VIRUS; MACACA; MONKEY DISEASES; PYRAZINES; RANDOM ALLOCATION; TREATMENT OUTCOME;

EID: 85052208222     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2409.180233     Document Type: Article

References (15)

1. Yun NE, Walker DH. Pathogenesis of Lassa fever. Viruses. 2012;4:2031–48. http://dx.doi.org/10.3390/v4102031
2. Sogoba N, Feldmann H, Safronetz D. Lassa fever in West Africa: evidence for an expanded region of endemicity. Zoonoses Public Health. 2012;59(Suppl 2):43–7. http://dx.doi.org/10.1111/j.1863-2378.2012.01469.x
3. Bausch DG, Hadi CM, Khan SH, Lertora JJ. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis. 2010;51:1435–41. http://dx.doi.org/10.1086/657315
4. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013;100:446–54. http://dx.doi.org/10.1016/j.antiviral.2013.09.015
5. Safronetz D, Rosenke K, Westover JB, Martellaro C, Okumura A, Furuta Y, et al. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci Rep. 2015;5:14775. http://dx.doi.org/10.1038/srep14775
6. Oestereich L, Rieger T, Lüdtke A, Ruibal P, Wurr S, Pallasch E, et al. Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever. J Infect Dis. 2016;213:934–8. http://dx.doi.org/10.1093/infdis/jiv522
7. Hensley LE, Smith MA, Geisbert JB, Fritz EA, Daddario-DiCaprio KM, Larsen T, et al. Pathogenesis of Lassa fever in cynomolgus macaques. Virol J. 2011;8:205. http://dx.doi.org/10.1186/1743-422X-8-205
8. World Health Organization. Weekly bulletin on outbreaks and other emergencies [cited 2018 Feb 5]. http://apps.who.int/iris/bitstream/handle/10665/260122/OEW5-2701222018.pdf;jsessionid=D19D5C 05BE101587B3AC601D56544764?sequence=1
9. Raabe VN, Kann G, Ribner BS, Morales A, Varkey JB, Mehta AK, et al.; Emory Serious Communicable Diseases Unit. Favipiravir and ribavirin treatment of epidemiologically linked cases of Lassa fever. Clin Infect Dis. 2017;65:855–9. http://dx.doi.org/10.1093/cid/cix406
10. Jahrling PB, Hesse RA, Eddy GA, Johnson KM, Callis RT, Stephen EL. Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin. J Infect Dis. 1980;141:580–9. http://dx.doi.org/10.1093/infdis/141.5.580
11. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med. 1986;314:20–6. http://dx.doi.org/10.1056/NEJM198601023140104
12. Hadi CM, Goba A, Khan SH, Bangura J, Sankoh M, Koroma S, et al. Ribavirin for Lassa fever postexposure prophylaxis. Emerg Infect Dis. 2010;16:2009–11. http://dx.doi.org/10.3201/eid1612.100994
13. Sissoko D, Laouenan C, Folkesson E, M’Lebing AB, Beavogui AH, Baize S, et al.; JIKI Study Group. Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016;13:e1001967. http://dx.doi.org/10.1371/journal. pmed.1001967
14. Westover JB, Sefing EJ, Bailey KW, Van Wettere AJ, Jung KH, Dagley A, et al. Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Res. 2016;126:62–8. http://dx.doi.org/10.1016/j.antiviral.2015.12.006
15. Mire CE, Cross RW, Geisbert JB, Borisevich V, Agans KN, Deer DJ, et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat Med. 2017;23:1146–9. http://dx.doi.org/10.1038/nm.4396